113 related articles for article (PubMed ID: 35952447)
1. New 4-thiazolidinone-based molecules Les-2769 and Les-3266 as possible PPARγ modulators.
Bar M; Skóra B; Tabęcka-Łonczyńska A; Holota S; Khyluk D; Roman O; Lesyk R; Szychowski KA
Bioorg Chem; 2022 Nov; 128():106075. PubMed ID: 35952447
[TBL] [Abstract][Full Text] [Related]
2. Anticancer properties of 4-thiazolidinone derivatives depend on peroxisome proliferator-activated receptor gamma (PPARγ).
Szychowski KA; Leja ML; Kaminskyy DV; Kryshchyshyn AP; Binduga UE; Pinyazhko OR; Lesyk RB; Tobiasz J; Gmiński J
Eur J Med Chem; 2017 Dec; 141():162-168. PubMed ID: 29031063
[TBL] [Abstract][Full Text] [Related]
3. 4-thiazolidinone-based derivatives rosiglitazone and pioglitazone affect the expression of antioxidant enzymes in different human cell lines.
Szychowski KA; Skóra B; Kryshchyshyn-Dylevych A; Kaminskyy D; Khyluk D; Lesyk R
Biomed Pharmacother; 2021 Jul; 139():111684. PubMed ID: 34243632
[TBL] [Abstract][Full Text] [Related]
4. Pyrrolidinedione-thiazolidinone hybrid molecules with potent cytotoxic effect in squamous cell carcinoma SCC-15 cells.
Finiuk N; Kaleniuk E; Holota S; Stoika R; Lesyk R; Szychowski KA
Bioorg Med Chem; 2023 Sep; 92():117442. PubMed ID: 37579525
[TBL] [Abstract][Full Text] [Related]
5. 4-Thiazolidinone-based derivatives do not affect differentiation of mouse embryo fibroblasts (3T3-L1 cell line) into adipocytes.
Szychowski KA; Skóra B; Kryshchyshyn-Dylevych A; Kaminskyy D; Tobiasz J; Lesyk RB; Gmiński J
Chem Biol Interact; 2021 Aug; 345():109538. PubMed ID: 34097888
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Anticancer and Antibacterial Activity of Four 4-Thiazolidinone-Based Derivatives.
Skóra B; Lewińska A; Kryshchyshyn-Dylevych A; Kaminskyy D; Lesyk R; Szychowski KA
Molecules; 2022 Jan; 27(3):. PubMed ID: 35164157
[TBL] [Abstract][Full Text] [Related]
7. The neuroprotective role of rosiglitazone in advanced glycation end product treated human neural stem cells is PPARgamma-dependent.
Chiang MC; Cheng YC; Nicol CJ; Lin CH
Int J Biochem Cell Biol; 2017 Nov; 92():121-133. PubMed ID: 28964868
[TBL] [Abstract][Full Text] [Related]
8. GW9662, a potent antagonist of PPARgamma, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARgamma agonist rosiglitazone, independently of PPARgamma activation.
Seargent JM; Yates EA; Gill JH
Br J Pharmacol; 2004 Dec; 143(8):933-7. PubMed ID: 15533890
[TBL] [Abstract][Full Text] [Related]
9. Rosiglitazone induces interleukin-1 receptor antagonist in interleukin-1beta-stimulated rat synovial fibroblasts via a peroxisome proliferator-activated receptor beta/delta-dependent mechanism.
Moulin D; Bianchi A; Boyault S; Sebillaud S; Koufany M; Francois M; Netter P; Jouzeau JY; Terlain B
Arthritis Rheum; 2005 Mar; 52(3):759-69. PubMed ID: 15751073
[TBL] [Abstract][Full Text] [Related]
10. Anti-proliferative effect of rosiglitazone in the human T-lymphocyte leukaemia cell line Jurkat cells.
Wei R; Yu F; Yang J; Gao H; Wang H; Hong T
Cell Biol Int; 2018 May; 42(5):515-524. PubMed ID: 29274299
[TBL] [Abstract][Full Text] [Related]
11. Rosiglitazone inhibits metastasis development of a murine mammary tumor cell line LMM3.
Magenta G; Borenstein X; Rolando R; Jasnis MA
BMC Cancer; 2008 Feb; 8():47. PubMed ID: 18261208
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of a novel series of alpha-aryloxy-alpha-methylhydrocinnamic acid derivatives as PPAR gamma agonists against a panel of human cancer cell lines.
Xiong X; Ye Y; Fu L; Dai B; Liu J; Jia J; Tang J; Li L; Wang L; Shen J; Mei C
Invest New Drugs; 2009 Jun; 27(3):223-32. PubMed ID: 18704263
[TBL] [Abstract][Full Text] [Related]
13. Thiazolidinedione drugs down-regulate CXCR4 expression on human colorectal cancer cells in a peroxisome proliferator activated receptor gamma-dependent manner.
Richard CL; Blay J
Int J Oncol; 2007 May; 30(5):1215-22. PubMed ID: 17390024
[TBL] [Abstract][Full Text] [Related]
14. Activation of peroxisome proliferator-activated receptor gamma inhibits cell growth via apoptosis and arrest of the cell cycle in human colorectal cancer.
Lin MS; Chen WC; Bai X; Wang YD
J Dig Dis; 2007 May; 8(2):82-8. PubMed ID: 17532820
[TBL] [Abstract][Full Text] [Related]
15. Study of antineoplastic action of novel isomeric derivatives of 4-thiazolidinone.
Chumak VV; Fil MR; Panchuk RR; Zimenkovsky BS; Havrylyuk DY; Lesyk RB; Stoika RS
Ukr Biochem J; 2014; 86(6):96-105. PubMed ID: 25816610
[TBL] [Abstract][Full Text] [Related]
16. Identification and characterisation of a prototype for a new class of competitive PPARγ antagonists.
Knape T; Flesch D; Kuchler L; Sha LK; Giegerich AK; Labocha S; Ferreirós N; Schmid T; Wurglics M; Schubert-Zsilavecz M; Proschak E; Brüne B; Parnham MJ; von Knethen A
Eur J Pharmacol; 2015 May; 755():16-26. PubMed ID: 25746464
[TBL] [Abstract][Full Text] [Related]
17. Rosiglitazone, a PPARγ agonist, ameliorates palmitate-induced insulin resistance and apoptosis in skeletal muscle cells.
Meshkani R; Sadeghi A; Taheripak G; Zarghooni M; Gerayesh-Nejad S; Bakhtiyari S
Cell Biochem Funct; 2014 Dec; 32(8):683-91. PubMed ID: 25431031
[TBL] [Abstract][Full Text] [Related]
18. Anticancer properties of 5Z-(4-fluorobenzylidene)-2-(4-hydroxyphenylamino)-thiazol-4-one.
Szychowski KA; Kaminskyy DV; Leja ML; Kryshchyshyn AP; Lesyk RB; Tobiasz J; Wnuk M; Pomianek T; Gmiński J
Sci Rep; 2019 Jul; 9(1):10609. PubMed ID: 31337851
[TBL] [Abstract][Full Text] [Related]
19. PPARγ-dependent pathway in the growth-inhibitory effects of K562 cells by carotenoids in combination with rosiglitazone.
Zhao H; Gu H; Zhang H; Li JH; Zhao WE
Biochim Biophys Acta; 2014 Jan; 1840(1):545-55. PubMed ID: 24036327
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of COX-2 expression by endocannabinoid 2-arachidonoylglycerol is mediated via PPAR-γ.
Du H; Chen X; Zhang J; Chen C
Br J Pharmacol; 2011 Aug; 163(7):1533-49. PubMed ID: 21501147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
